Publication

A review of retroperitoneal liposarcoma genomics.

Tyler, Robert
; ; 
Taniere, Philippe
; 
Almond, Max
; 
Ford, Samuel
; 
Desai, Anant
; 
Beggs, Andrew
Abstract
Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their extremity counterparts. Within their subtypes - well differentiated (WDL), dedifferentiated (DDL), myxoid (MLS) and pleomorphic (PLS) - they exhibit a diverse genomic landscape. With recent advances in next generation sequencing, the number of studies exploring this have greatly increased. The recent literature has deepened our understanding of the hallmark MDM2/CDK4 amplification in WDL/DDL and addressed concerns about toxicity and resistance when targeting this. The FUS-DDIT3 fusion gene remains the primary focus of interest in MLS with additional potential targets described. Whole genome sequencing has driven identification of novel genes and pathways implicated in WDL/DDL outside of the classic 12q13-15 amplicon. Due to their rarity; anatomical location and histologic subtype are infrequently mentioned when reporting the results of these studies. Reports can include non-adipogenic or extremity tumours, making it difficult to draw specific retroperitoneal conclusions. This narrative review aims to provide a summary of retroperitoneal liposarcoma genomics and the implications for therapeutic targeting.
MIDER Authors
Almond, Max
Ford, Samuel
Desai, Anant
Citations
Altmetric:
Date
2020-03-28
Type
Article
Other
Subject
Genetics
Collections
UHB Oncology
Reports
Show all metadata
Citation
Tyler R, Wanigasooriya K, Taniere P, Almond M, Ford S, Desai A, Beggs A. A review of retroperitoneal liposarcoma genomics. Cancer Treat Rev. 2020 Jun;86:102013. doi: 10.1016/j.ctrv.2020.102013. Epub 2020 Mar 28
Journal / Source Title
Cancer Treatment Reviews
DOI
10.1016/j.ctrv.2020.102013
URI
http://hdl.handle.net/20.500.14200/7624
PMID
32278233
Publisher
Elsevier
Publisher’s URL
http://www.sciencedirect.com/science/journal/03057372
Publisher’s statement
Note / Copyright